Biogen Idec Loses Another Board Member
This article was originally published in The Pink Sheet Daily
Executive Summary
Lame duck R&D chief Pickett will also give up directorship, boosting Carl Icahn's percentage of seats - for now.
You may also be interested in...
But Who’s Counting? Icahn Wins A Biogen Seat, Another Is “Too Close To Call”
After a drama-packed shareholder meeting on June 3, Carl Icahn claims he won two of four contested seats on the 13-person, Biogen Idec board
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.